News & Resources

Olshan Client Biotechnology Value Fund’s Investments Highlighted

May 19, 2010

BioWorld® 20th Anniversary Edition recently featured Olshan's client, Biotechnology Value Fund, in an article about the Fund’s investments in various pharmaceutical related companies including the Fund’s recent involvement with Avigen, Inc. and proposing a new model in which biotech shareholders are provided protection in this inherently risky business. Adam W. Finerman and Jason W. Soncini represent Biotechnology Value Fund in its dealings with Avigen.

Attorneys